Wuhan Hite Biopharmaceutical Co., Ltd.
Wuhan Hite Biopharmaceutical Co., Ltd.
Wuhan Hite Biopharmaceutical Co., Ltd.
WUHAN HITECK BIOLOGICAL PHRAMA CO., LTD
Wuhan Hiteck Biological Pharma Co., Ltd. is a publicly listed biopharmaceutical company (Shenzhen Stock Exchange: 300683) dedicated to the discovery and development of innovative biologics and small-molecule therapeutics. Originating from the Medical School of Wuhan University, Hiteck has built an integrated R&D and manufacturing infrastructure supporting end-to-end drug development and translation. The company operates a state-of-the-art pharmaceutical industrial park with GMP-compliant facilities, enabling efficient progression from discovery to clinical and commercial supply.
MORE +Focus on Hiteck
Product Center
The company is dedicated to the research, development, and manufacturing of pharmaceuticals in the fields of the nervous system and oncology.
A national class I biological new drug, mouse nerve growth factor for injection (Jinlujie), and a class I genetic engineering biological new drug, recombinant mutant human tumor necrosis factor related apoptosis inducing ligand (CPT) have been put on the market.
MORE +
INNOVATIVE RESEARCH AND DEVELOPMENT
The company is a high-tech enterprise in Hubei Province. There are post doctoral mobile workstations approved by the Ministry of human resources and social security of the people's Republic of China, and "Hubei rare disease drug engineering technology research center" and "Hubei high tech innovative enterprise" approved by the provincial science and technology department. Five basic technology platforms have been established, and pilot bases have been established to promote the industrialization of relevant achievements and efficient transformation to the market.
Copyright © Wuhan Hite Biopharmaceutical Co., Ltd. All Rights Reserved.